Glyscend taps CEO to lead oral obesity, type 2 diabetes candidate; Ex-Travecta chief bounces back after company shutdown

08 Sep 2023

Phase 2Executive Change

As a new wave of type 2 diabetes and obesity drugs takes the industry by storm, Glyscend Therapeutics has tapped a new CEO to lead the charge for its candidate designed to mimic metabolic surgery. Sapan Shah is taking the driver’s seat at Glyscend as founding CEO Ashish Nimgaonkar shifts to other roles as chief medical officer and head of R&D, the company announced on Tuesday. The news comes just a few months after Glyscend unveiled topline data from a Phase IIa suggesting its lead candidate, GLY-200 , helped type 2 diabetes patients achieve significant reductions in blood glucose and a decrease in body weight. The company hopes the oral drug will have the same effects as metabolic surgery without the cost and complications from the invasive procedure.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Glyscend, Inc.

Travecta Therapeutics Pte Ltd.

Indications

ObesityDiabetes Mellitus, Type 2

Targets

Drugs

GLY-200

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.